Revenio updates its financial guidance for the year 2021
Revenio Group’s exchange rate adjusted net sales are estimated to grow very strongly from the previous year and profitability is to remain at a good level without non-recurring items. COVID-19 pandemic continues to cause uncertainty related to the markets.
Previous earnings guidance published on April 23, 2021:
COVID-19 pandemic continues to cause uncertainty related to the markets. Revenio Group’s exchange rate adjusted net sales are estimated to grow strongly from the previous year and profitability is to remain at a good level without non-recurring items.
Revenio Group Corporation
Board of Directors
For further information, please contact:
CEO Jouni Toijala, tel. +358 50 484 0085
Robin Pulkkinen, CFO, tel. +358 50 505 9932
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
The Revenio Group in brief
Revenio is a leading company in ophthalmological devices and software solutions. Revenio Group’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, the Group’s eye care software platform Oculo brings together clinical communication, telehealth, remote patient monitoring, and data analytics capabilities.
Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy and Oscare Medical Oy.
In 2020, the Group’s net sales totaled EUR 61.1 million and its operating profit amounted to EUR 17.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.